Repligen Corporation (RGEN) |
| 130.59 -2.74 (-2.06%) 06-12 16:00 |
| Open: | 133.57 |
| High: | 135.725 |
| Low: | 130.49 |
| Volume: | 1,269,638 |
| Market Cap: | 7,366(M) |
| PE Ratio: | 143.51 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 158.53 |
| Resistance 1: | 135.73 |
| Pivot price: | 123.67 |
| Support 1: | 114.26 |
| Support 2: | 100.99 |
| 52w High: | 175.77 |
| 52w Low: | 100.99 |
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
| EPS | 0.900 |
| Book Value | 37.330 |
| PEG Ratio | 1.94 |
| Gross Profit | 7.191 |
| Profit Margin (%) | 6.73 |
| Operating Margin (%) | 8.90 |
| Return on Assets (ttm) | 1.2 |
| Return on Equity (ttm) | 2.5 |
Thu, 11 Jun 2026
RBC Capital Resumes Repligen Corp (RGEN) Stock Coverage. Here’s Its View - Insider Monkey
Tue, 09 Jun 2026
Repligen Corp (RGEN) Shares Surge 3.8% -- What GF Score of 83 Te - GuruFocus
Mon, 08 Jun 2026
Repligen Corporation (RGEN) Stock Analysis: Unlocking a 43.98% Upside in Bioprocessing Innovation - DirectorsTalk Interviews
Mon, 08 Jun 2026
Repligen (RGEN) down 3.2% since last earnings report: Can it rebound? - MSN
Thu, 04 Jun 2026
Repligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow - Seeking Alpha
Mon, 01 Jun 2026
Repligen Corporation (RGEN) Stock Analysis: Unpacking a 44% Potential Upside for Investors - DirectorsTalk Interviews
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |